 Jaguar planning for launch of CanaleviaTM for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA ACCESSWIRE September 23, 2021 Jaguar Health, Inc. NASDAQ:JAGX today announced that it was informed on September 21, 2021 by the FDAs Center for Veterinary Medicine CVM that the Target Animal Safety TAS technical section of the companys application for conditional approval of Canalevia for chemotherapy-induced diarrhea CID under the Minor UseMinor Species MUMS section of The Minor Use and Minor Species Animal Health Act of 2004 has been deemed Complete. The TAS section - the last of the four major technical sections of Jaguars application - describes testing undertaken to show that a drug candidate is safe for use under the conditions for which the drug will be prescribed following its approval. 